| In ZINC since | Heavy atoms | Benign functionality |
|---|---|---|
| October 4th, 2005 | 33 | No |
Popular Name: (-)-EPIGALLOCATECHIN GALLATE (-)-EPIGALLOCATECHIN GALLATE
Find On: PubMed — Wikipedia — Google
CAS Numbers: 84650-60-2 , 989-51-5 , CAS# 989-51-5 , [989-51-5]
"(-)-Epigallocatechin gallate, 98%"
(-)-epigallocatechin 3-gallate
(-)-Epigallocatechin 3-O-gallate
(-)-Epigallocatechin Gallate Hydrate
(-)-Epigallocatechin gallate, 95%
(-)-epigallocatechin-3-gallate
(2R,3R)-5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzo
3-O-(4-Hydroxybenzoyl)epigallocatechin
5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate
989-51-5; C09731; Epigallocatechin 3-gallate
CPD000449288; Epigallocatechin gallate; 989-51-5
CPD000449288; Epigallocatechin gallate; SAM001247031
EGCG (Epigallocatechin gallate )
epigallocatechin-3-monogallate
[5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl] 2,3,4-trihydroxybenzoate
| Type pH range | xlogP | Des A‑Pol Apolar desolvation (kcal/mol) | Des Pol Polar desolvation (kcal/mol) | H Don H-bond donors | H Acc H-bond acceptors | Chg Net charge | tPSA (Ų) | MWT Molecular weight (g/mol) | RB Rotatable bonds | DL |
|---|---|---|---|---|---|---|---|---|---|---|
| Ref Reference (pH 7) | 2.25 | -6.71 | -20.66 | 8 | 11 | 0 | 197 | 458.375 | 4 | ↓ |
| Hi High (pH 8-9.5) | 2.25 | -5.81 | -60.24 | 7 | 11 | -1 | 200 | 457.367 | 4 | ↓ |
| Hi High (pH 8-9.5) | 2.25 | -5.67 | -56.02 | 7 | 11 | -1 | 200 | 457.367 | 4 | ↓ |
| Note Type | Comments | Provided By |
|---|---|---|
| Molecular_Solubility | 1.562 | Bitter DB |
| MP | 212 | TCI |
| Purity | >98% | Fluorochem |
| biological_use | Antioxidant | IBScreen Bioactives |
| Target | DNA Methyltransferase,HER2,Telomerase,EGFR | Selleck Chemicals |
| Patent Database Links | EP0819433; EP0842660; EP1005862; EP1103550; EP1232756; EP1767097; EP1770090; EP1938816; EP1961310; US2005049284; US2005176939; US2005256178; US2006134286; US2006241154; US2007184105; US2008241289; WO2005027901; WO2008153938 | ChEBI |
| PUBCHEM_SUBSTANCE_COMMENT | NCC_SAMPLE_SUPPLIER : Tocris Cookson Ltd.; NCC_SUPPLIER_STRUCTURE_ID : 100468 | NIH Clinical Collection via PubChem |
| Target | Others | Selleck Chemicals |
| UniProt Database Links | PPAP_HUMAN | ChEBI |
| PUBCHEM_SUBSTANCE_COMMENT | SAMPLE_SUPPLIER: Tocris Bioscience; SUPPLIER_STRUCTURE_ID: 100468 | NIH Clinical Collection via PubChem |
| mechanism | Shows anti-HIV activity. Tumour promotion inhibitor, putative cancer chemopreventive agent. Implicated in occup. asthma in green tea factories | IBScreen Bioactives |
| Target | Tyrosine-protein kinase Fyn(P06241)&Transcription factor p65(Q04206)&Inhibitor of nuclear factor kappa-B kinase subunit beta(O14920)&Interferon regulatory factor 3(Q14653)&Serine/threonine-protein kinase TBK1(Q9UHD2)&Angiotensinogen(P01019)&Epidermal grow | Herbal Ingredients Targets |
| Code | Description | Organism Class | Affinity (nM) | LE (kcal/mol/atom) | Type |
|---|---|---|---|---|---|
| 6PGD-1-E | 6-phosphogluconate Dehydrogenase (cluster #1 Of 1), Eukaryotic | Eukaryotes | 720 | 0.26 | Binding ≤ 10μM |
| BCL2-1-E | Apoptosis Regulator Bcl-2 (cluster #1 Of 2), Eukaryotic | Eukaryotes | 234 | 0.28 | Binding ≤ 10μM |
| ERG1-3-E | Squalene Monooxygenase (cluster #3 Of 3), Eukaryotic | Eukaryotes | 690 | 0.26 | Binding ≤ 10μM |
| KCNH2-1-E | HERG (cluster #1 Of 5), Eukaryotic | Eukaryotes | 6026 | 0.22 | Binding ≤ 10μM |
| MET-1-E | Hepatocyte Growth Factor Receptor (cluster #1 Of 1), Eukaryotic | Eukaryotes | 3300 | 0.23 | Binding ≤ 10μM |
| MK14-2-E | MAP Kinase P38 Alpha (cluster #2 Of 3), Eukaryotic | Eukaryotes | 2210 | 0.24 | Binding ≤ 10μM |
| MMP14-1-E | Matrix Metalloproteinase 14 (cluster #1 Of 3), Eukaryotic | Eukaryotes | 6800 | 0.22 | Binding ≤ 10μM |
| MMP2-2-E | 72 KDa Type IV Collagenase (cluster #2 Of 3), Eukaryotic | Eukaryotes | 9600 | 0.21 | Binding ≤ 10μM |
| Q965D5-1-E | Enoyl-acyl-carrier Protein Reductase (cluster #1 Of 1), Eukaryotic | Eukaryotes | 8 | 0.34 | Binding ≤ 10μM |
| Q965D6-1-E | 3-oxoacyl-acyl-carrier Protein Reductase (cluster #1 Of 2), Eukaryotic | Eukaryotes | 300 | 0.28 | Binding ≤ 10μM |
| Q965D7-2-E | Fatty Acid Synthase (cluster #2 Of 2), Eukaryotic | Eukaryotes | 400 | 0.27 | Binding ≤ 10μM |
| G6PD-1-F | Glucose-6-phosphate 1-dehydrogenase (cluster #1 Of 1), Fungal | Fungi | 250 | 0.28 | Binding ≤ 10μM |
| Z50142-1-O | Influenza A Virus (A/PR/8/34(H1N1)) (cluster #1 Of 2), Other | Other | 391 | 0.27 | Functional ≤ 10μM |
| Z50425-3-O | Plasmodium Falciparum (cluster #3 Of 22), Other | Other | 9900 | 0.21 | Functional ≤ 10μM |
| Z80156-1-O | HL-60 (Promyeloblast Leukemia Cells) (cluster #1 Of 12), Other | Other | 9400 | 0.21 | Functional ≤ 10μM |
| Q72547-1-V | Human Immunodeficiency Virus Type 1 Reverse Transcriptase (cluster #1 Of 6), Viral | Viruses | 730 | 0.26 | Binding ≤ 10μM |
| Uniprot | Swissprot | Description | Affinity (nM) | LE (kcal/mol/atom) | Type |
|---|---|---|---|---|---|
| Q965D6_PLAFA | Q965D6 | 3-oxoacyl-acyl-carrier Protein Reductase, Plafa | 300 | 0.28 | Binding ≤ 1μM |
| 6PGD_HUMAN | P52209 | 6-phosphogluconate Dehydrogenase, Human | 720 | 0.26 | Binding ≤ 1μM |
| BCL2_HUMAN | P10415 | Apoptosis Regulator Bcl-2, Human | 234.422882 | 0.28 | Binding ≤ 1μM |
| Q965D5_PLAFA | Q965D5 | Enoyl-acyl-carrier Protein Reductase, Plafa | 186 | 0.29 | Binding ≤ 1μM |
| Q965D7_PLAFA | Q965D7 | Fatty Acid Synthase, Plafa | 400 | 0.27 | Binding ≤ 1μM |
| G6PD_YEAST | P11412 | Glucose-6-phosphate 1-dehydrogenase, Yeast | 250 | 0.28 | Binding ≤ 1μM |
| Q72547_9HIV1 | Q72547 | Human Immunodeficiency Virus Type 1 Reverse Transcriptase, 9hiv1 | 730 | 0.26 | Binding ≤ 1μM |
| ERG1_RAT | P52020 | Squalene Monooxygenase, Rat | 690 | 0.26 | Binding ≤ 1μM |
| Q965D6_PLAFA | Q965D6 | 3-oxoacyl-acyl-carrier Protein Reductase, Plafa | 300 | 0.28 | Binding ≤ 10μM |
| 6PGD_HUMAN | P52209 | 6-phosphogluconate Dehydrogenase, Human | 720 | 0.26 | Binding ≤ 10μM |
| BCL2_HUMAN | P10415 | Apoptosis Regulator Bcl-2, Human | 234.422882 | 0.28 | Binding ≤ 10μM |
| Q965D5_PLAFA | Q965D5 | Enoyl-acyl-carrier Protein Reductase, Plafa | 186 | 0.29 | Binding ≤ 10μM |
| Q965D7_PLAFA | Q965D7 | Fatty Acid Synthase, Plafa | 400 | 0.27 | Binding ≤ 10μM |
| G6PD_YEAST | P11412 | Glucose-6-phosphate 1-dehydrogenase, Yeast | 250 | 0.28 | Binding ≤ 10μM |
| MET_HUMAN | P08581 | Hepatocyte Growth Factor Receptor, Human | 10000 | 0.21 | Binding ≤ 10μM |
| KCNH2_HUMAN | Q12809 | HERG, Human | 6025.59586 | 0.22 | Binding ≤ 10μM |
| Q72547_9HIV1 | Q72547 | Human Immunodeficiency Virus Type 1 Reverse Transcriptase, 9hiv1 | 730 | 0.26 | Binding ≤ 10μM |
| MK14_HUMAN | Q16539 | MAP Kinase P38 Alpha, Human | 2210 | 0.24 | Binding ≤ 10μM |
| MMP14_HUMAN | P50281 | Matrix Metalloproteinase 14, Human | 6800 | 0.22 | Binding ≤ 10μM |
| MMP2_HUMAN | P08253 | Matrix Metalloproteinase-2, Human | 9600 | 0.21 | Binding ≤ 10μM |
| ERG1_RAT | P52020 | Squalene Monooxygenase, Rat | 690 | 0.26 | Binding ≤ 10μM |
| Z80156 | Z80156 | HL-60 (Promyeloblast Leukemia Cells) | 9400 | 0.21 | Functional ≤ 10μM |
| Z50142 | Z50142 | Influenza A Virus (A/PR/8/34(H1N1)) | 391 | 0.27 | Functional ≤ 10μM |
| Z50425 | Z50425 | Plasmodium Falciparum | 9900 | 0.21 | Functional ≤ 10μM |
| Description | Species |
|---|---|
| activated TAK1 mediates p38 MAPK activation | |
| Activation of BAD and translocation to mitochondria | |
| Activation of gene expression by SREBF (SREBP) | |
| Activation of Matrix Metalloproteinases | |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | |
| Activation of the AP-1 family of transcription factors | |
| ADP signalling through P2Y purinoceptor 1 | |
| BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members | |
| CDO in myogenesis | |
| Cholesterol biosynthesis | |
| Collagen degradation | |
| Degradation of the extracellular matrix | |
| DSCAM interactions | |
| EPH-ephrin mediated repulsion of cells | |
| ERK/MAPK targets | |
| KSRP destabilizes mRNA | |
| NOD1/2 Signaling Pathway | |
| Oxidative Stress Induced Senescence | |
| p38MAPK events | |
| Pentose phosphate pathway (hexose monophosphate shunt) | |
| Platelet sensitization by LDL | |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-l | |
| Sema4D mediated inhibition of cell attachment and migration | |
| The NLRP1 inflammasome | |
| VEGFA-VEGFR2 Pathway | |
| Voltage gated Potassium channels |
